The federal reclassification of cannabis from Schedule I to Schedule III marks a historic shift in U.S. policy. Industry leaders weigh in on what rescheduling means for research, taxation, banking access, and the future of regulated cannabis.
The U.S. decision to reschedule cannabis to Schedule III signals federal recognition of medical value. Industry voices examine 280E tax relief, research access, patient impact, and the unresolved limits of reform.
President Donald Trump signs an Executive Order reclassifying cannabis from Schedule I to Schedule III, marking a major federal shift welcomed by the American Cannabis Collective and patient advocates.
Rumors suggest President Trump may reschedule marijuana from Schedule I to III. Industry leaders react with optimism and caution as the change could impact research, taxes, banking, and state policies, while critics warn of confusion and uneven effects for small businesses.
A hidden clause in Congress’s spending bill could erase 95% of the hemp-derived market overnight. Framed as “safety,” the move signals a deeper push toward consolidation—and a warning shot for what may come next.
Congress’s 2025 spending bill includes a sweeping change to federal hemp law, redefining legal hemp and effectively banning most hemp-derived THC products. Industry leaders warn the move could “wipe out” 95% of the market, while advocates say it underscores the need for unified cannabis regulation.
President Donald Trump is expected to announce “Make Cannabis Great Again,” rescheduling cannabis to Schedule III. The move would legalize medical use across the U.S., spark global reforms, and trigger a worldwide race in cannabis research and development.
With Trump open to cannabis rescheduling and the DEA making it a priority, industry leaders see a historic shift ahead. Schedule III could ease taxes, boost research, and spur growth—but experts warn it’s only the first step toward real federal reform.
A Senate bill proposing a sweeping ban on intoxicating hemp products has been delayed for one year—but stakeholders warn that even non-psychoactive CBD could be at risk.
A new House GOP spending bill seeks to halt cannabis rescheduling, threatening federal reform progress even as support grows among Republicans and youth voters.
A man died running from an ICE raid at a legal cannabis farm. This isn't just about one raid—it's about an industry built on invisible labor, silence, and survival. If you're profiting from the plant, it's time to ask: Who's bleeding to keep it in your hands?
Florida’s adult-use cannabis campaign is gaining momentum, but a new law signed by Governor DeSantis revokes medical marijuana cards from patients with drug convictions—signaling a sharp crackdown even as legalization efforts ramp up for 2026.
A powerful coalition of athletes and entertainers, including Mike Tyson, Allen Iverson, Kevin Durant, and Wyclef Jean, has urged Donald Trump to lead on cannabis reform—calling for marijuana rescheduling, clemency for nonviolent offenders, and fair banking access.
Shahbaaz Kara, a Canadian entrepreneur, bridges cultures and discusses Canada's evolving identity, leadership, and cannabis market. He reflects on Trudeau's legacy, Trump's tariffs, and the future of the cannabis industry, offering insight into the opportunities and challenges shaping North America.
Robert F. Kennedy Jr.'s confirmation as Secretary of Health and Human Services marks a pivotal moment for cannabis policy. Experts discuss his potential influence on cannabis rescheduling, research, and regulation, with hopes for more progressive federal policies in the U.S.
